Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
Date:8/8/2011

fiscal 2010.
  • Total operating expenses were $48.1 million in the first nine-months of fiscal 2011 compared to $20.3 million in the comparable period for fiscal 2010.
  • Cash used in operations was $42.5 million in the first nine-months of fiscal 2011.
  • Net loss for the first nine-months of fiscal 2011 was $42.6 million, or $0.36 per share, compared with a net loss of $17.0 million, or $0.20 per share for the comparable period in fiscal 2010.

  • NUEDEXTA RevenueFor the quarter ended June 30, 2011, the company reported NUEDEXTA gross and net revenue of $2.2 million and $1.9 million respectively. NUEDEXTA revenue is recognized using a deferred revenue recognition model, meaning that NUEDEXTA capsule shipments to wholesalers are initially recorded as deferred revenue and later recognized as revenue when the product has left the distribution channel and is no longer subject to a right of return, effectively representing reported end-user prescriptions and non-retail shipments of NUEDEXTA capsules.

    Business HighlightsRecent highlights for the company include:

  • In July, the company met with the European Medicines Agency (EMA) to discuss plans for filing a marketing authorization application (MAA) for NUEDEXTA for the treatment of pseudobulbar affect. Based on the outcome of the meeting, the company plans to request an accelerated review process and to file for approval of NUEDEXTA using the data package which served as the basis for the U.S. Food and Drug Administration approval of NUEDEXTA.  The timing of the company's MAA filing is subject to reaching an agreement with the EMA on a pediatric investigation plan for NUEDEXTA, which may occur before the end of calendar year 2011.
  • In April, the company filed an Investigational New Drug application with the U.S. Food and Drug Administration to begin a large Phase II clinical trial of AVP-923. The objectives of the PRIME study (Pain Research In Multiple sclErosis) a
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
    2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
    4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
    5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
    7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
    8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
    9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
    10. Avanir Pharmaceuticals to Present at Three Conferences in March
    11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... /PRNewswire-iReach/ -- ScriptPro has been certified by the ... Security Framework (CSF). According to Russ Hailey ... appreciate this rigorous, top-to-bottom audit. Security-minded customers depend ... signifies. Our business partners need to know we ... PROCESS: ScriptPro,s internal security processes and controls were ...
    (Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
    (Date:8/21/2014)... SAN FRANCISCO , Aug. 21, 2014 ... U.S. Food and Drug Administration (FDA) has ... to detect atrial fibrillation (AFib), the most ... analysis process (algorithm) instantly detects if patients ... recordings taken on the mobile phone based ...
    Breaking Medicine Technology:ScriptPro Achieves HITRUST Certification 2ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2
    ... Industry-Funded Immune Globulin Study Uncovers Sample,Manipulation, Design ... -- An analysis,released today critically examined a ... autism and Rh immune globulin,(RhIg) injections, some ... extensive design flaws, the,analysis uncovered manipulation of ...
    ... OSS, the Netherlands, June 27, 2007-Organon, the human,healthcare ... two,out of three Phase III clinical trials with ... have reached,their randomization target. , ,Corifollitropin alfa ... first of a new class of gonadotropins (a ...
    Cached Medicine Technology:Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 2Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 3Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
    (Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Black mothers ... babies, and here,s one possible reason why: Hospitals in ... nursing than those in areas with more white residents, ... support breast-feeding are much less common in medical centers ... from the U.S. Centers for Disease Control and Prevention ...
    (Date:8/21/2014)... born at a low birth weight puts black women at ... The findings may partly explain high diabetes rates among ... low birth weight, the researchers added. Their study of ... low birth weight were 13 percent more likely to develop ... The risk of diabetes was 40 percent higher in those ...
    (Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... A combination of therapy and antidepressants appears to best ... study reports. Four out of five people suffering ... full recovery when treated with cognitive therapy plus antidepressant ... combination didn,t work much better than drugs alone in ...
    (Date:8/21/2014)... August 21, 2014 Transvaginal mesh ... Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. ... 14th, the Court has established new stipulated evidence ... handling, division, storage and preservation. (In re C.R. ...
    (Date:8/21/2014)... 21, 2014 Seattle, WA chiropractors ... Eastlake Chiropractic and Massage Center have recently ... team. Rina Lang, LMP and Mike Larios, LMP ... of massage techniques, and have developed their expertise working ... is particularly important in a clinical environment where massage ...
    Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3
    ... are used in some men to help them improve ... characteristics. Apparently the same patches can be used in ... their sexual desire and activity. ,In a study ... have looked at 447 women diagnosed with hypoactive sexual ...
    ... want to know answers to everything. This gains special// importance ... often have we questioned the diseases that make our precious ... ,Researchers in a breakthrough have unraveled the mystery surrounding heart ... failure, the heart uses too much fatty acid and not ...
    ... disease is responsible for nearly half (49 per cent) ... million people each year. Reducing cholesterol is one of ... ,Both soy protein and plant sterols extracted from ... foods market, with the US Food and Drug Administration ...
    ... D in bone development and teeth// strengthening is well known. Children ... the body with this vital nutrient. Vitamin D is produced in ... exposed to sunlight too. So much so that parents want their ... vitamin, which is free in nature! All this is done to ...
    ... tomographic colonography (CTC) depicts cancers and other clinically important conditions ... at very little additional cost, according to a study in ... finding cancer outside the colon may be as significant as ... Yee, M.D., Chief of Radiology at the Veterans Affairs Medical ...
    ... causes that can cause hearing loss in people apart// ... and type 1 diabetes. The researches are featured in ... ,In the first study researchers have found a previously ... form of hearing loss due to a lesion of ...
    Cached Medicine News:Health News:Testosterone Patches Found To Increase Sexual Desire In Menopausal Women 2Health News:Calcium-Vitamin D Combo For Reduced Fracture Risk 2Health News:Calcium-Vitamin D Combo For Reduced Fracture Risk 3Health News:Virtual Colonoscopy May Be Better Than Real-time Colonoscopy 2Health News:Studies On Hearing Loss Discovers New Causes 2
    The P45 Ultrasonic Workstation provides the highest ultrasound resolution for imaging....
    EchoScan US-2500 is available in a single configuration or in combination with the A scan for maximum cost efficiency....
    PremierEdge Stab Knives - 30....
    ... in the 21st century requires ... Alcon® UltraScan® imaging system responds ... at clinical echographic needs in ... permits step-by-step processing to collect ...
    Medicine Products: